^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Rectal Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/20/2020
    Excerpt:
    Rectal cancer:.Primary treatment...Consider ([nivolumab ± ipilimumab] or pembrolizumab [preferred]) (dMMR/MSI-H only)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Colorectal Cancer)
    New
    Title:

    FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

    Excerpt:
    The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

    Excerpt:
    ...- Patient must have MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) tumors based on immunohistochemistry or PCR (polymerase chain reaction)...
    Trial ID:
    EA2201
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Oncologist
    Title:

    Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer

    Published date:
    10/06/2021
    Excerpt:
    After MSI-H/dMMR was confirmed, the patient was treated with ICIs (1 mg/kg ipilimumab at day 1 and 3 mg/kg nivolumab at day 1 and 15). A complete clinical response was documented at day 21 after start of treatment.
    DOI:
    10.1002/onco.13955